Spero Therapeutics (SPRO)
NASDAQ:SPRO
Total Valuation
Spero Therapeutics has a market cap or net worth of $129.68M. The enterprise value is $98.10M.
Market Cap$129.68M
Enterprise Value$98.10M
Share Statistics
Spero Therapeutics has 57,891,495 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,891,495
Owned by Insiders5.32%
Owned by Institutions25.29%
Financial Efficiency
Spero Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is -0.04%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)-0.04%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee1.86M
Profits Per Employee267.88K
Employee Count32
Asset Turnover0.87
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spero Therapeutics is 15.2. Spero Therapeutics’s PEG ratio is -0.14.
PE Ratio15.2
PS Ratio2.19
PB Ratio2.21
Price to Fair Value2.21
Price to FCF-10.34
Price to Operating Cash Flow-10.38
PEG Ratio-0.14
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 59.62M and earned 8.57M in profits. Earnings per share was 0.15.
Revenue59.62M
Gross Profit0.00
Operating Income-24.00K
Pretax Income8.83M
Net Income8.57M
EBITDA-24.00K
Earnings Per Share (EPS)0.15
Cash Flow
In the last 12 months, operating cash flow was -12.62M and capital expenditures 0.00, giving a free cash flow of -12.62M billion.
Operating Cash Flow-12.62M
Free Cash Flow-12.62M
Free Cash Flow per Share-0.22
Dividends & Yields
Spero Therapeutics pays an annual dividend of $0.015, resulting in a dividend yield of ―
Dividend Per Share$0.015
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.71
52-Week Price Change222.77%
50-Day Moving Average2.35
200-Day Moving Average2.33
Relative Strength Index (RSI)38.33
Average Volume (3m)305.58K
Important Dates
Spero Therapeutics upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Spero Therapeutics as a current ratio of 7.59, with Debt / Equity ratio of 4.91%
Current Ratio7.59
Quick Ratio7.59
Debt to Market Cap0.01
Net Debt to EBITDA1.56K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spero Therapeutics has paid 261.00K in taxes.
Income Tax261.00K
Effective Tax Rate0.03
Enterprise Valuation
Spero Therapeutics EV to EBITDA ratio is -3.88K, with an EV/FCF ratio of -7.38.
EV to Sales1.56
EV to EBITDA-3.88K
EV to Free Cash Flow-7.38
EV to Operating Cash Flow-7.38
Balance Sheet
Spero Therapeutics has $40.27M in cash and marketable securities with $2.90M in debt, giving a net cash position of $37.37M billion.
Cash & Marketable Securities$40.27M
Total Debt$2.90M
Net Cash$37.37M
Net Cash Per Share$0.65
Tangible Book Value Per Share$1.05
Margins
Gross margin is 11.94%, with operating margin of -0.04%, and net profit margin of 14.38%.
Gross Margin11.94%
Operating Margin-0.04%
Pretax Margin14.82%
Net Profit Margin14.38%
EBITDA Margin-0.04%
EBIT Margin-0.04%
Analyst Forecast
The average price target for Spero Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-67.38%
EPS Growth Forecast-1076.54%